Tuspetinib
Cat. No.：YN270711
CAS No. ：2294874-49-8
| 产品名称: | Tuspetinib |
| CAS No.: | 2294874-49-8 |
| Chemical Name: | rel-5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)-2-pyrimidinamine |
| Synonyms: | HM43239 |
| 分子量: | 501.06546 |
| 分子式: | C29H33ClN6 |
| SMILES: | ClC1=CN=C(NC2=CC(C3CC3)=CC(CN4C[C@H](N[C@H](C4)C)C)=C2)N=C1C5=CNC6=CC(C)=CC=C56 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Tuspetinib (HM43239) 是具有口服活性的选择性FLT3抑制剂，IC50值为 1.1 nM (FLT3 野生型)、1.8 nM (FLT3 ITD 突变型) 和 1.0 nM (FLT3 D835Y 突变型)。Tuspetinib 作为可逆的 I 型抑制剂直接抑制FLT3的激酶活性，并调节 p-STAT5, p-ERKSYK, JAK1/2 和 TAK1。Tuspetinib 抑制白血病细胞的增殖，诱导细胞凋亡 (apoptosis)。 |
| IC50和靶点: | [{name:"FLT3 WT:1.1 nM (IC50)"},{name: "FLT3 ITD:1.8 nM (IC50)"},{name: "FLT3 D835Y:1.0 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Bae, I.H., Kim, J.S., Choi, J.Y., et al.Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the sameUS 10,870,639 B2,(2020)
